Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab in IgG4-Related Disease
NCT04540497Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Dec 2020
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of inebilizumab in IgG4-related disease (IgG4-RD), sponsored by Amgen. Started Dec 2020; status: active, not recruiting.
02
Drugs
inebilizumab
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT04540497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540497.